---
title: "Ensysce enrolls first patient in final phase of PF614-MPAR-102 overdose-protection trial"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/290962389.md"
description: "Ensysce Biosciences has enrolled the first patient in the final phase of its PF614-MPAR-102 clinical trial, evaluating MPAR overdose-protection technology. Previous data showed the drug maintains therapeutic exposure while limiting it during overdoses. The National Institute on Drug Abuse supports the study, aiming to confirm protective effects across broader dosing scenarios and potentially secure a differentiated safety label for this opioid."
datetime: "2026-06-26T12:04:16.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/290962389.md)
  - [en](https://longbridge.com/en/news/290962389.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/290962389.md)
---

# Ensysce enrolls first patient in final phase of PF614-MPAR-102 overdose-protection trial

-   Ensysce Biosciences initiated the final stage of its PF614-MPAR-102 clinical study, enrolling the first patient to evaluate MPAR overdose-protection technology. \* Earlier clinical data have already been presented, showing the drug maintained therapeutic exposure at prescribed use while limiting exposure under excessive oral dosing. \* The final-stage readout is expected in the future, aiming to confirm the protective effect across a broader set of dosing scenarios. \* Program positioning centers on an opioid designed to curb overdose risk without relying on traditional abuse-deterrent approaches, supporting a potential differentiated safety label. \* The study is supported by the National Institute on Drug Abuse, which could reduce development cost and bolster external validation. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ensysce Biosciences Inc. published the original content used to generate this news brief on June 26, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [ENSC.US](https://longbridge.com/en/quote/ENSC.US.md)
- [ENSCW.US](https://longbridge.com/en/quote/ENSCW.US.md)

## Related News & Research

- [07:30 ETAnoka County Expands Opioid Prevention Efforts with Continuing Education Modules](https://longbridge.com/en/news/293207364.md)
- [Celldex Treatment Fails To Relieve Chronic Itch, Abandons Prurigo Nodularis Study](https://longbridge.com/en/news/293468293.md)
- [10:49 ETLawdragon 500X Honors Nachawati Law Group Partners Erin Wood and Charlie Stern as Next Generation Legal Leaders](https://longbridge.com/en/news/293230822.md)
- [Incannex starts screening patients in Phase 2 DReAMzz trial of IHL-42X for sleep apnea](https://longbridge.com/en/news/293607970.md)
- [FDA advisers recommend against the first unapproved peptide on second day of meeting](https://longbridge.com/en/news/293780907.md)